key: cord-0757914-ldjgu849
authors: Mohney, K. L.; Link, C. B.; Kanwar, M. K.; Veasey, T. M.
title: COVID-19 Vaccination Motivation and Hesitancy in Heart Transplant Recipients During a Global Health Crisis
date: 2022-04-30
journal: The Journal of Heart and Lung Transplantation
DOI: 10.1016/j.healun.2022.01.1580
sha: 332e633d953fde045bb0e674964253ad86e98916
doc_id: 757914
cord_uid: ldjgu849

Purpose Heart transplant (HT) recipients are at increased risk of acquiring SARS-CoV-2 (COVID-19) and infection related complications, which can lead to long term morbidity and mortality due to their immunosuppressed status. COVID-19 vaccination is strongly recommended for transplant recipients. However, the motivating and limiting factors to vaccination in HT recipients remain unknown. Methods A 26 question survey was mailed to all adult HT recipients at our center to assess the number of patients who received a COVID-19 vaccine as well as motivating and limiting factors to vaccination. Surveys with 3 or more incomplete answers were excluded. Results Ninety (36.1%) of 249 HT recipients returned the survey, with 5 surveys excluded and 85 evaluated. Selected responses are reported in the table. Of assessed surveys, 82 (96.5%) patients received a COVID-19 vaccine with primary motivating factor to protect their own health (86.9%). A majority of respondents were very (45.9%) or moderately concerned (23.5%) about getting COVID-19 infection. While most patients (57.7%) reported no concern about getting the vaccine, 23 respondents listed a vaccine-related concern. A high percentage (67.9%) of patients reported obtaining certain information about the vaccine which they could not determine to be true or false. The most trusted source for vaccine information was a transplant provider (80%). Of 3 non-vaccinated respondents, none listed a specific concern related to the vaccine; 2 of the 3 (66.7%) had previously confirmed COVID-19 infection. Conclusion A high percentage of responding HT recipients received a COVID-19 vaccine. Patients were primarily motivated to protect their own health and reported low concern about receiving a vaccine. Transplant providers were a highly trusted source of information, suggesting an important role for the transplant team in encouraging vaccination.

(400) Mucormycosis After Heart Transplantation: A Single Center Experience S. Hockney, 1 P. Santoiemma, 2 A. Goyal, 1 R. Kumar, 3 K. Ghafourian, 4 and V. Stosor. 5 1 Northwestern University Feinberg School of Medicine, Chicago, IL; 2 Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, IL; 3 Division of Infectious Diseases, Medstar Georgetown University Hospital, Washington, DC; 4 Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, IL; and the 5 Division of Infectious Diseases and Organ Transplantation, Northwestern University Feinberg School of Medicine, Chicago, IL.

Purpose: To define the epidemiology and examine outcomes of heart transplant recipients (HTR) with mucormycosis. Methods: We performed a retrospective 1:4 case-control study in HTR with and without mucormycosis from 6/2005-5/2021. Statistical analyses were conducted using R version 3.6.1. Continuous variables were analyzed using student's T test and categorical variables using Fisher's exact tests. Results: The prevalence of mucormycosis was 1.5% (n=7; 6 HTR, 1 HTkidney recipient) and occurred at a mean 109 d post-HT (range 25-310 d). Those with mucormycosis were predominantly male (85.7%) and white (85.7%) with mean age was 59 y. For induction, 4 cases received basiliximab and 2 received thymoglobulin. Three cases received antifungal prophylaxis with posaconzole (n=2) or voriconazole (n=1). Infection usually involved the lung (n=6), but also the rhinocerebrum (n=1) and skin/soft tissue (n=1), with species including Rhizopus (n=3), Cunninghamella (n=1), and other Mucorales species unknown (n=3). Initial treatment included liposomal Amphotericin-B (n=6) and isavuconazole (n=1). Two cases underwent lung resection, and one had a leg amputation for surgical treatment. Two patients expired due to mucormycosis at 25 d and 95 d post-HT. Compared to HTR without mucormycosis, cases were older (59y v. 48y, p=0.03) and were more likely to have underlying lung disease (71.4% vs 17.9%, p=0.01) and need hemodialysis in the peri-transplant period (71.4% vs 57.1%, p=0.03). There was more diabetes (71.4% vs 57.1%, p=0.68) and kidney disease (71.4% vs 57.1%, p=0.68) in the mucormycosis group, but neither reached statistical significance. There was no difference in ATG induction between the two groups (29% vs 29%, p=1). HTR with mucormycosis were also more likely to have bacterial infections after transplant (85.7% vs 35.7%, p=0.0381). HTR with mucormycosis had higher 1 yr infection-related mortality (42.9% vs 0%, p=0.005) and a trend toward higher 1 yr overall mortality (28.6% vs 7.1%, p=0.17) compared to HTR without mucormycosis. Conclusion: In this study, prevalence of mucormycosis after HT was low, but resulted in high 1 yr infection-related and overall mortality. Older age, lung disease and hemodialysis emerged as univariate predictors for mucormycosis. Most mucormycosis infections (71%) occurred in the first 3 months following transplant, even in patients on mold-active antifungal prophylaxis. Purpose: Heart transplant (HT) recipients are at increased risk of acquiring SARS-CoV-2 (COVID-19) and infection related complications, which can lead to long term morbidity and mortality due to their immunosuppressed status. COVID-19 vaccination is strongly recommended for transplant recipients. However, the motivating and limiting factors to vaccination in HT recipients remain unknown. Methods: A 26 question survey was mailed to all adult HT recipients at our center to assess the number of patients who received a COVID-19 vaccine as well as motivating and limiting factors to vaccination. Surveys with 3 or more incomplete answers were excluded. Results: Ninety (36.1%) of 249 HT recipients returned the survey, with 5 surveys excluded and 85 evaluated. Selected responses are reported in the table.

Of assessed surveys, 82 (96.5%) patients received a COVID-19 vaccine with primary motivating factor to protect their own health (86.9%). A majority of respondents were very (45.9%) or moderately concerned (23.5%) about getting COVID-19 infection. While most patients (57.7%) reported no concern about getting the vaccine, 23 respondents listed a vaccine-related concern. A high percentage (67.9%) of patients reported obtaining certain information about the vaccine which they could not determine to be true or false. The most trusted source for vaccine information was a transplant provider (80%). Of 3 non-vaccinated respondents, none listed a specific concern related to the vaccine; 2 of the 3 (66.7%) had previously confirmed COVID-19 infection. Conclusion: A high percentage of responding HT recipients received a COVID-19 vaccine. Patients were primarily motivated to protect their own health and reported low concern about receiving a vaccine. Transplant providers were a highly trusted source of information, suggesting an important role for the transplant team in encouraging vaccination. Purpose: The purpose of this study is to compare patient characteristics of those who died from Covid-19 compared to death from all other causes. Methods: The UNOS registry was queried to compare transplant recipients who died of Covid (n=300) vs non-Covid causes (n=5,644) from 2018 to 2021. Patient characteristics including age, sex, ethnicity, smoking, medical comorbidities, and time of transplant hemodynamics were evaluated. Baseline characteristics were compared using the Mann Whitney U test and Chi square test as appropriate. Survival was compared using Kaplan-Meier survival analysis. Results: The population who died from Covid was significantly older (56.6y vs 49.8y, p <0.001), had a higher percentage of males (79.3% vs 74.3%, p=0.049), had a higher incidence of diabetes (39.1% vs 27.8%, p<0.001), increased incidence of smoking (53.7% vs 42% p<0.001), and had a higher cardiac output (4.7L/min vs 4.5L/min, p=0.032). Causians had significantly lower incidence of death from Covid (62.7% vs 67.2%, p=0.031). Donor age, waiting times, baseline renal function, ischemic times, and cardiopulmonary support time did not differ significantly between the two populations. Conclusion: Widely studied risk factors for Covid pneumonia mortality such as age, male sex, diabetes, and smoking were consistent in the post heart transplant population. Communities of color were disproportionately affected by Covid. Furthermore, Covid deaths were not associated with inferior cardiac characteristics at time of transplant. More investigation is warranted to investigate the effect of more widely available immunologic and pharmacological therapies on high-risk subpopulations following heart transplant.

(403)

Intravenous Immunoglobulin is Associated with Lower Rates of Reinfection in Solid Organ Recipients with Infection and Secondary Antibody Deficiency: A Multicenter Randomized Clinical Trial J. Carbone, 1 J. Montanchez, 2 J

Purpose: Cytomegalovirus (CMV) infection commonly affects heart transplants (HT). Guidelines recommend 3-6 months of prophylaxis (ppx) for primary mismatch (D+/R-) with (val)ganciclovir. We sought to assess the frequency of CMV infection subsequent to our protocol change where ppx was decreased from 12 to 6 months. Methods: This was a single-center, retrospective study of adults who underwent CMV D+/R-HT from 2009-2020 with a follow up of 18 months (5 patients had shorter follow up but all developed CMV infection and were included for analysis). Results: Overall, 76 HT recipients met inclusion criteria. Patient characteristics are shown in Table 1 . In the 6 and 12 month ppx protocols, there were 23 (71.9%) and 12 (27.3%) CMV infection episodes, respectively. Of these infections, 46.9% and 9.1% of HT were hospitalized. Kaplan-Meier showed a significant difference between the two groups ( Fig. 1) . Median time to infection from transplant was 246 and 398 days, with most infections occurring after stopping ppx. More patients in the 12 month protocol received induction and CMV immunoglobulin. While nearly all patients were on a calcineurin inhibitor, mycophenolate (MP), and prednisone at 3 months post-HT, fewer were on MP and prednisone at 6 and 12 months in the 6 month ppx cohort and more patients were on sirolimus or everolimus in the same group. Conclusion: Patients in the 6 month CMV ppx protocol had significantly higher incidence of CMV infection and hospitalization. While a longer ppx protocol may theoretically increase risk of leukopenia and financial burden, our study suggests 12 months of ppx is a better strategy when considering that hospitalization for CMV is no trivial matter.